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The use of computational methods in drug design is valuable in reducing costs and time. It allows 
researchers to optimise lead compounds and to predict and measure their binding affinity. This 
helps streamline the drug discovery process. This thesis discusses the use of computational 
methods to discover novel compounds for the inhibition of the SRPK1 protein. The protein plays 
a significant role in angiogenesis through the regulation of anti-angiogenic VEGF 
isoform formation. Many studies have shown that inhibition of SRPK1 has a correlation to 
reduced angiogenesis. Inhibitors of the protein can be useful in the treatment of a number of 
conditions like neovascular eye disease and cancer.   
Four novel compounds were discovered through pharmacophore modelling and docking studies 
which was used to measure the strength of the interaction between compound and 
target. Though not all the compounds could be synthesised, four other compounds underwent 
synthesis. Unfortunately, in vitro toxicity and binding studies could not be conducted. The in 
vitro testing however was conducted on SRPIN340 after it was successfully synthesised. The 
toxicity tests for SRPIN340 showed toxicity around a concentration of 25 µM. 
 
  




Angiogenesis is the formation and maintenance of new blood vessels from pre-existing vasculature.2 
This is not to be confused with vasculogenesis- the de novo creation of blood vessels.3 Angiogenesis 
is a constant and vital process in the body due to its role in growth and development, wound healing 
and disease. It is also one of the first and most critical processes to begin in embryo formation and 
growth.4 Blood vessels are important in the distribution and diffusion exchange of oxygen, nutrients, 
antibodies and hormones. Therefore, changes in activity or regulation of angiogenesis can prove 
detrimental to the body and may bolster the activity of certain diseases and conditions. Diseases 
which include cancer, rheumatoid arthritis and wet age-related macular degeneration (AMD). Due to 
this, angiogenesis has become a target in the control and treatment in the above diseases and other 
ischaemic illnesses.4, 5  
2.1 The Angiogenic Process 
 
Angiogenesis occurs as a series of events, but these events can occur in two different ways. Both 
ways occur in utero and throughout life from the infanthood to adulthood and they are: sprouting 
and intussusceptive angiogenesis.2 
Intussusceptive angiogenesis is the formation of blood vessels by the growth and extension of the 
capillary wall into the lumen to split one vessel into two new ones.6, 7 On the other hand, sprouting 
angiogenesis which is more pertinent to this research, is characterised by the formation of `sprouts’ 
from endothelial cells (EC) to create new blood vessels and this happens in multiple stages. 
Firstly, in the case of a hypoxic environment, oxygen sensing mechanisms begin EC activation using 
angiogenic factors such as VEGF (Vascular Endothelial Growth Factor). Then, the capillary wall is 
degraded by extracellular proteinases and from this, the degraded part of the begins to serve as a 
branch point for the new blood vessel.  
8 | P a g e  
 
ECs begin to proliferate to make sprouts which then migrate into the extracellular membrane (ECM) 
towards the area with a high concentration of angiogenic stimuli. Tip cells on the sprouts have 
processes called filopodia which secrete high levels of proteolytic enzymes that help create a route 
in the ECM for the sprout.8 They also have heavy concentrations of VEGF receptors (VEGFR2) which 
help them direct the sprouts to where they can sense high levels of the angiogenic stimuli.9 When 
enough of the tip cells reach their destination, there is a reorganisation of the ECs to form tubules.10 
 
2.2 VEGF  
 
As mentioned before, the ECs proliferate and move towards the VEGF concentration gradient. VEGF 
is a polypeptide growth factor recognised to play a significant role in inducing angiogenesis.9 The 
VEGF family mainly consists of six members with each having specialised roles. They are: VEGF-A 
(the first to be identified), VEGF-B, VEGF-C, VEGF- D, VEGF- E (from the orf parapox virus) and 
placenta growth factor (PIGF).11 VEGF-A is perhaps the most important in terms of the angiogenic 
pathway and coupled with exon splicing of the VEGF-A gene, molecular variants of this same protein 
can be made with only slight differences in the total amino acid number. In humans, the main five 
variants are VEGF-A121, VEGF-A145, VEGF-A165, VEGF-A189 and VEGF-A206. VEGF-A165 is one of the most 
pro-angiogenic isoforms whilst the VEGF-A165b isoform is anti-angiogenic 12therefore highlighting the 
changes splicing can have on the function of a protein. The splicing process that cells use to 
determine which of these isoforms to generate are specially regulated by the proteins SPRK1 








SRPKs are a group of enzymes that specifically phosphorylate the serine residues in serine/arginine 
proteins (SR proteins). SR proteins are an essential class of splicing factors which in turn is essential 
in pre- mRNA processing. Phosphorylation of these proteins by SRPKs is necessary for them to 
conduct both constitutive and alternative splicing (Figure 1). 1Splicing is the process of removing 
introns from pre-mRNA and consequently joining the exons to form mature RNA.13 This reaction is 
catalysed by spliceosomes. Constitutive splicing is the process where the exons are spliced in the 
same way and order, always with a spliceosome. On the other hand, alternative splicing allows for 
variations in the expression of genes.1, 14 Different sites for splicing are selected with placing 







Figure 1: Constituted and Alternative splicing by serine/arginine proteins (SRP) with the possible mature mRNA products for 
each mechanism. Adapted from Wang et al. Intron domains characterised by the U circles. 
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SRPK1 is key in the up-regulation of the alternative splicing of VEGF-A to create pro-angiogenic 
isoforms through the phosphorylation of the SRSF1.15  SRPK1 is usually anchored in the cytoplasm 
but translocated to the nucleus. When in the nucleus, an accumulation of SR proteins in the 
cytoplasm is induced subsequently altering downstream splicing events. Due to this important role, 
it is imperative that SRPK2 is tightly regulated. SRPK1 has been seen to be upregulated in cancers 
such as breast16, colon, pancreatic and lung cancers.17 Where SRPK1 expression has been reduced, 
studies showed an increase in pro-apoptotic proteins sensitised breast cancer cells to apoptosis.18 
Another study showed a correlation between SRPK1 expression and the preferential metastasis of 
breast cancer cells into the brain and the lungs19. To target the inhibition of SRPK1 can, therefore, be 
an avenue where angiogenesis can be reduced. 
Over the years some compounds have been found to have an inhibitory effect on the SPRK1 protein. 
With some being small molecule inhibitors that fit into the active site cleft of kinase core of the 
protein. One of these small molecule inhibitors is SRPIN340 (Figure 2) which was determined by 
Fukuhara et al.20 It has shown a Ki of 0.89 µM and IC50 of 0.14 µM in mice.  
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Three components of the SRPIN340 molecule make it good at binding to the SRPK1 protein. The X-
ray structure of the protein reveals a hydrophobic pocket created by a kinase hinge region next to a 
helix in the SRPK1 insertion domain packs which is shown in Figure 3 and Figure 4.21 When this 
pocket is analysed when bound to SRPIN340, the interactions between molecule and protein can be 
seen. The CF3 group orients the molecule towards the hydrophobic pocket allowing the molecule to 
enter the binding site. This is due to its small size but very electronegative nature. The piperidine and 
isonicotinamide groups serve as hydrogen bond acceptors which interact with the altered DFG and 






Figure 2: X- Ray structure of SRPK1 bound to SRPIN340 showing the large and small lobes. 
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Figure 4: Left portion shows the molecular interactions between SPRIN340 and SRPK1 residues. SPRIN340 is coloured in 
dark grey and protein residues are in white. The right shows more detailed regions of the SRPK1 protein. Left portion is 
from the RSCB PDB21 and the right portion is adapted from Batson et. al. 23 
 
Though SRPIN340 shows great promise, it’s not ideal as an antiangiogenic drug. Firstly, it lacks 
selectivity in its inhibition of kinases. Not only has SRPIN340 been shown to inhibit SRPK1, but it has 
also shown inhibition is SRPK220 and this could lead to higher toxicities and unpredictable effects. 
Secondly, SPRIN340 is almost insoluble in water and best dissolved in DMSO with an estimated logP 
of 3.589. This makes administration of the drug difficult. For oral ingestions, solubility in water is 
imperative as drugs with low water solubility often require higher doses to have a therapeutic effect 
and the use of higher doses of a drug can cause problems when it comes to toxicity.24, 25  
However, SRPIN340 is a small molecule inhibitor. This is an advantage because some of the current 
treatments of neovascular eye conditions and some cancers employ the use of monoclonal 
antibodies. The use of these antibodies usually requires a subcutaneous injection and sometimes 
directly to the afflicted area. This can result in low patient compliance as doing it in a pain-free way 
can be challenging. Also, there are risks of infections and other adverse effects on the injection site. 
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2.4 Angiogenesis in Disease 
 
Mammalian cells can only be at maximum 100 to 200 µm from the nearest blood vessel to access 
and receive the oxygen and nutrients they require.26 When the number of cells increase, more blood 
vessels are needed to provide the constant stream of oxygen and nutrients needed and this is when 
angiogenesis is necessary3. Without angiogenesis and a limited amount of blood vessels, the size of 
the group of cells is restricted. In a healthy mammal, the process of angiogenesis is highly regulated 
by pro- and anti-angiogenic proteins. These molecules are exploited in angiogenesis- dependent 
diseases. 
2.4.1 Macular Degeneration 
 
Age-related macular degeneration is one of the leading causes of blindness especially amongst the 
elderly in the developed world.27  This condition is caused by the damage to the macula of the 
retina28 as seen in Figure 5. Though early on there are little to no symptoms, sufferers begin to 
experience a slow worsening of vision in the affected eye. In most cases, there is not complete loss 
of vision, but the reduced vision makes it difficult for sufferers to perform daily tasks such as driving 
and reading. 
 
Figure 5: A drawn anatomy of the eye showing the macula- the part of the eye most affected by AMD.29 
14 | P a g e  
 
 
Some of the most common symptoms of macular degeneration are distorted vision (where straight 
lines may appear wavy), blurred vision and a loss in contrast sensitivity.30 As mentioned before, 
macular degeneration rarely leads to complete vision loss. This is because the macula only takes 
about 2% of the area of the retina, therefore, leaving the remaining 98% of the peripheral field.31 
However, even though such a small portion is taken by the macular almost half of the processing 
power of the visual cortex goes to information gained from the macula. 
The three main stages to the development of AMD are the early, intermediate and late stages. In 
AMD, there is an accumulation of deposits named drusen (deposits usually made from proteins and 
lipids) in the macular and it is the size of this buildup, that is used to characterise the stages of 
AMD.32 
Early AMD is characterised with medium-sized drusen, around the width of a human hair with 
intermediate AMD having a larger amount of drusen. In the late stages, enough damage has 
occurred to the retina that loss of vision has begun.32 This late-stage can be divided into two sub-
categories:  wet and dry AMD. 
 
Dry AMD accounts for about 80 to 90% of all cases and tends to have a slow progression.33 In this 
category, large amounts of drusen have accumulated as well as an irreversible loss of retinal cells. In 
some cases, there is a progression to the wet type. Wet AMD, also known as neovascular AMD, is 
caused by the abnormal increase in the growth of blood vessels in the choriocapillaris34 as seen in 
figure 6. These abnormal blood vessels tend to be fragile and can easily break leading to the release 
of proteins and blood in the eye which goes on to cause damage that is irreversible to the 
photoreceptors resulting in a rapid loss in vision.34 
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Figure 6: Frontal section of the eye showing the difference in the macula in Wet and Dry AMD.35 
 
 
Dry AMD has no medical treatment available on the other hand wet AMD has a number of 
treatments. Laser coagulation in conjunction with medication has been known to stop and 
sometimes even reverse angiogenesis in the condition. Bevacizumab and ranibizumab (structures in 
Figure 9) have been shown to inhibit angiogenesis with similar efficacy to Laser coagulation. Other 
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2.4.2 Angiogenesis and Cancer 
 
The proliferation and metastatic spread of cancer cells is dependent on the increased growth of 
vasculature for the required stream of nutrients, metabolites and oxygen. It has been shown that 
pre-cancerous cells or tissue become cancerous after acquiring the ability to switch on 
angiogenesis.36 This ability can be induced through different mechanisms such as hypoxia-induced 
tumour angiogenesis.37 
 Metastasis is made efficient when tumour cells infiltrate blood vessels, travel around the circulatory 
system and relocate to a different part of the body such as an organ, bone or tissue and 
proliferate.38, 39 This highlights the vital role angiogenesis plays in the growth and metastatic nature 
of tumour cells. Further studies have even gone to show that when cancer cells are starved of blood 
circulation, they only grew to be around 2 mm in diameter, unlike cells which were in environments 
where angiogenesis could be switched on. The cells grew to a much bigger size.40  
2.4.2.1 Tumour Angiogenesis 
 
To gain the nutritional needs required to grow and expand, cancer cells use co-opt existing 
vasculature and then go on to form vasculature of their own down the line as seen Figure 7.41 
 
 
Figure 7: Tumour angiogenesis in the lung. Cancer cells are in red, vasculature labelled with anti-PECAM antibodies in 
green. 
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Oxygen has been known to be crucial in the regulation of angiogenesis. In blood vessels, both the 
smooth muscle (SMC) and endothelial cells (ECs) have mechanisms specifically for the sensing of 
oxygen. Such mechanisms include the use of heme-oxygenases and oxygen-sensitive NADPH 
oxidases.42  Another type of oxygen sensors interacts with the hypoxia-inducible transcription factor 
(HIF) family which can initiate the expression of many genes vital to cell survival and angiogenesis. 
These features are attributed to normal blood vessel structures.43 When co-opting, the tumour 
continues to expand and take over more of the adjacent vasculature but through this takeover, the 
morphology of the vessels become altered. This alteration goes on to affect its physiology and its 
therapeutic response.44 
Unlike normal blood vessels, tumour- associated vessels are not hierarchic, or efficient in the 
delivery of nutrients to a tumour. This lack of efficiency is due to the inefficient coating of smooth 
muscle on the vessel. They also are randomly structured with highly irregular patterns of branching45 
(Figure 8).41 Another alteration in morphology in tumours are that the ECs are hyperactive by 
releasing proteins such as endothelial growth factor (EGF), VEGF and oestrogen. All these proteins 
encourage additional endothelial cell growth. 
 
Figure 8: Vasculature co-opting by tumour cells (TC). (A): TC migrating across the membrane and associating with normal 
nearby vessels. (B) Co-opted vessel modification after a period of time by the TCs.41 
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As stated previously, tumour vasculature is inefficient in the provision of nutrients and oxygen to a 
tumour. This causes hypoxia and acidosis in the cancer cells and if left too long, necrosis and 
apoptosis are induced in the tumour46 however, hypoxia coupled with angiogenesis mutations in the 
cell leads to the activation of hypoxia-induced angiogenesis37, 47 which starts with upregulation of the 
VEGF mRNA and protein.48 
 
2.4.2.2 Current Anti-angiogenesis Cancer Treatments 
 
There are many different cancer treatments that target different pathways and angiogenesis 
inhibitors. By stopping or reducing the production of the new blood vessels, the tumour growth can 
be halted through starvation. These compounds can then be used in conjunction with other blood 
vessels in cancer treatments. 
Angiogenesis inhibitors can be placed in two classes: direct and indirect inhibitors. The direct 
inhibitors target the ECs.49 They prevent the proliferation and migration of ECs due to the cells 
responding to inducers like VEGF and Platelet-derived growth factor (PDFG)50. Examples of such 
inhibitors are angiostatin, canstatin, tumstatin and arrestin but these examples are fragment 
peptides of larger proteins that are released through proteolysis.51 
 Indirect inhibitors target tumours and tumour- associated cells. They also inhibit the expression or 
function of pro-angiogenic proteins like VEGF and EGF.52 A lot of anti-angiogenesis approved drugs 
fall in this category.  Some of these drugs on the market are; thalidomide, gefitinib, bevacizumab, 
sunitinib and axitinib which are illustrated in figure 9. 

































sunitinib (5)  
Figure 9: Structures of some of the current anti-angiogenic drugs used in the treatment of cancer. 
 
Once used as an anti-emetic drug, thalidomide has been used in treating myeloma and cancers that 
produce VEGF and similar angiogenic cytokines like placental growth factor (PLGF).53 It inhibits the 
phosphorylation of Akt which is significant in the pathways of many pro-angiogenic factors. Due to 
its side effects of the drug such as thromboembolism and neuropathy, analogues have been made 
like pomalidomide. Thalidomide as a therapy on its own has not been shown to have much 
significant anti-angiogenic effect yet, has proven effective against many different myeloma54 when 
coupled with dexamethasone which is a corticosteroid commonly used in the treatment of 
rheumatic problems. 
Bevacizumab (Avastin) is a humanized monoclonal anti-VEGF- A antibody. It is used to treat lung, 
renal, ovarian and glioblastomas though it is not effective in breast cancers. It binds to extracellularly 
to VEGF-A to prevent binding to VEGFRs found on the surfaces of ECs.55 Some other monoclonal 
antibodies used are ramucirumab and IMC-18F1 with others like cetuximab and volociximab being 
under consideration. 
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Another class of anti-angiogenesis drug are the receptor tyrosine kinase inhibitor small molecules 
(RTKIs). Examples of these are sunitinib and axitinib seen in figure 9 with sunitinib being primarily 
used in the treatment of kidney and renal cell carcinoma. They inhibit the enzymatic activity of the 
tyrosine kinase fragment found in multiple receptors involved in angiogenesis pathways.  
 
2.5 Computational Methods in Drug Discovery 
 
The discovery and development of drugs is often a very long, costly and complex process. A lot of 
the time and money spent in the process is usually due to synthesising and testing leads. Over the 
years, the use of computational methods in the drug discovery pipeline has become increasingly 
more important. Computer-aided drug design (CADD) has become a way to reduce costs and time 
because of its lead optimisation abilities. It has become especially more significant with its ability to 
create in silico models of molecules and isolating desired attributes such as binding affinity and 
specificity of the proposed molecule.  
Many heavily used drugs on the market today were discovered through computational methods and 
these drugs are found in therapies for HIV/AIDS and other viral diseases and cancer. In influenza, 
one of the most notable examples is the drug Zanamivir (illustrated in Figure 10).  The viral target 
used was the neuraminidase enzyme. By studying and exploiting its structure through x-ray 
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Neuraminidase is an enzyme important to the influenza virus. It cleaves the terminal sialic acid 
residues on the surface of host cells and the virus itself. It also helps in the release of the newly 
formed virus from the surface of infected cells.56, 57 Inhibitors to this enzyme tend to be sialic acid 
analogues and they work through competitive inhibition by binding to the active site. This leaves no 
room for the enzyme to bind to the sialic acid on the surface of the host cell. When the protein 
neuraminidase was crystallised, this allowed a 3D structure of the active site to be explored. From 
this, inhibitors could be created58. A lead compound 2-deoxy-2,3-didehydro-N-acetyl neuraminic acid 
(Neu5Ac2en) was found to be a small molecule inhibitor and this was used as a scaffold to find 
derivatives59.  Using the structure of the active site, modifications of Neu5Ac2en could be tested to 
see its potency. With improvements in X-ray crystallography, important residues in the active sites 
were identified which resulted in knowing what substitutions to make. An example was finding that 
swapping the C4 hydroxyl group with a more basic group. After even more improvements with X-ray 
crystallography, it was discovered that an even larger basic group could be accommodated. So, a 
guanidyl group was used as the basic group to make 4-deoxy-4-guanidino-Neu5Ac2en. This was then 

























Figure 10: Inhibitors Neu5Ac2n and the Zanamivir 
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2.5.1 Important Processes 
 
One of the most important processes used in computational techniques in drug discovery is 
molecular recognition. In this process, in silico calculations of the interaction between a small 
molecule and a protein can be made. Through this, the behaviour of these interactions can be seen 
on an atomic level of detail which would be more difficult to do experimentally. Seeing this 
behaviour is done by linking structural and energetic properties using physics-based energy 
functions such as molecular mechanics. Interactions on a molecular level can be studied using 
docking studies.  
Molecular docking is a method used in predicting the most suitable orientation of a ligand when 
complexed to an active site as seen in Figure 11. The primary aim is to find an optimised 
conformation for both ligand and receptor to a point where the free energy of the complex is 
minimised. Docking studies are particularly important in not just finding optimum orientation but to 
also predicting the binding affinity of the ligand.  
 
 
Figure 11: Schematic illustration of the docking of a molecule/ligand (green) to the active site of a target protein to form 
a complex. Docking studies would highlight the ligand in the optimum orientation and conformation (circled).  




Different forces affect how the ligand binds to the active site of the target. Some include 
electrostatic forces which are charges that reside in both ligand and active site. Steric forces are 
influenced by entropy which is where the complex naturally seeks to find the conformation with the 
least free energy. Solvent-related forces come from structural changes of the solvent and occur 
when things like ions and proteins bring about structural changes to the solvent. Such forces include 
hydrogen bond and hydrophobic interactions.  
Docking studies occur in a number of stages. Firstly, a three-dimensional structure of the receptor 
should be built. An example of a source for such structures is the PDB and if not available online, X-
ray crystallography of the protein can be used. When the structure is obtained, it is essential for the 
active sites within the receptor to be identified. Some proteins may have multiple active sites but 
the one of pertinence should be located.  The next stage is the ligand selection and preparation. 
Ligands can be created by the researcher or obtained from databases like PubChem and ZINC. Once 
this library has been collected, docking can begin. Using software like AUTODOCK and GRAMM, the 
ligand is docked unto the active and site and the molecular interactions are monitored. A function 
score or binding affinity is given and from this, molecules in the library can be ranked. Due to this, 
docking can be used to screen out non-active molecules or those with particularly low binding 
affinities. It can also be used in optimisation to find substitutions that can be made to the lead 
compounds to make more selective and potent analogues.   
Another important process used through computation methods is virtual screening. This is the 
process of taking a large library of available small compounds and evaluating their bioactivity 
computationally. Different software such as DOCK, KNIME and Pharmit can use a scoring method 
(either pre-set or customised) to rank the molecules in the library to highlight the most bioactive. 
Software like Pharmit use pharmacophore studies to score and rank the molecules. 
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It was once thought that particular functional groups in a molecule were responsible for the 
molecules biological effect, but the term pharmacophore was coined by Scheuler who defines it as 
“a molecular framework that carries the essential features responsible for the drug’s biological 
activity.”.60 However, a pharmacophore is more an abstract concept and should not be reduced to 
just functional groups like guanidines or to scaffolds like prostaglandins. The use of pharmacophores 
has become very important in CADD. Here, molecular patterns are labelled according to their 
features such as being anionic, aromatic or cationic. Through this, different molecules can be 
compared using these pharmacophore labels rather than using actual atoms or functional groups.   
With these patterns, a pharmacophore model can be built. Most models have spheres to highlight 
each feature or label with the size of each sphere representing the room for deviation from the 
exact position. This deviation from the exact position can be used as a method for ranking the 
molecules in a library and this property is called the root mean square deviation (RMSD). By coupling 
the RMSD score with docking scores, it possible to screen through libraries to find molecules with a 
high binding affinity that do not deviate too much from the original position of the lead compound.  
2.5.2 Structures in Drug Discovery 
 
When using structure-targeted methods for finding new lead compounds, it is imperative that a 
correct and accurate structure is used- especially in mechanisms concerning ligand binding, 
enzymatic functions and protein-protein interactions. Techniques such as x-ray crystallography serve 
as a powerful method to determine structures of target proteins although they provide static 
structures and the process of making the proteins into crystals may be at times very difficult. In this 
research, the X-ray structure for SRPK1 plays a significant role when conducting pharmacophore 
studies. 
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3.  Project Aims  
 
The process of angiogenesis is essential to survival and when the process is exploited through 
upregulation or suppression, it can a very detrimental effect on life. Cancers and neovascular 
diseases are examples where the effect of the upregulation of angiogenesis can be seen. 
Chemotherapies can be made to target and inhibit pro-angiogenic factors like SRPK1. A current 
molecule known for inhibiting is SRPK1 is SRPIN340. Whilst this shows promise, SRPIN340 lacks 
hydrophilicity which makes it hard for oral administration. It also is not very potent meaning a higher 
dose are needed for a therapeutic effect which can consequently bring about toxicities.  
This project aims to create novel compounds that can serve as a more potent and hydrophilic 
substitute for SRPIN340. This will be done through pharmacophore and docking studies using made 
libraries from ZINC and Swiss Bioisostere. From this process, a few molecules will be chosen for 
synthesis. After synthesis, the molecules will be complexed with SRPK1 to establish inhibition. The 
SRPK1 used will be induced and harvested from transformed E. coli BL21(DE3) cells. Toxicity studies 
of both SRPIN340 and the newly synthesised molecules will be done using two strains of breast 












4.1 Protein Expression and Purification 
The materials used to make the media, buffers and other compounds were bought from Sigma-
Aldrich and Fisher Scientific. The BL21(DE3) E. coli were bought from Novagen whilst the 
recombinant plasmids were donated by the J. Adams research group. All bacterial growth and 
protein expression procedures were carried out in sterile conditions with the use of a Bioquell PLC 
Microflow biological safety cabinet. The protocols used in cell culturing and protein expression and 
purification were adapted from Aubol et. al61  
Medium Preparation 
In this process, Luria Broth (LB) was made from NaCl (10 g/L), yeast extract (5 g/L) and Tryptone (20 
g/L) with the pH adjusted to 7.5. Conical flasks were each filled with about 200 mL of media and 
sealed using a bung and aluminium foil. The flasks were then autoclaved at 121oC, 15 psi for 20 
minutes for sterilisation. 
Cell Transformation and Culturing 
The recombinant plasmids encoding the SRPK1 gene were transformed into the E. coli BL21(DE3) cells 
through heat shock and grown on LB agar plate containing the antibiotic carbenicillin at 37oC 
overnight. Single colonies were taken from the plate and added to 10 mL of LB media containing 
carbenicillin (100 mg/mL) which were in 50mL falcon tubes. The colonies were then grown in agitated 
conditions at 220 rpm and 37oC. They were left to grow until the media became opaque in colour. 3mL 
of this was added to every 200 mL portion of media in conical flasks with added 200 µg carbenicillin 
(100 mg/mL). The flasks were then put into an incubator to stir at 220 rpm and 37oC until the OD500 
was about 0.7 
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Protein Expression 
1 mL of a 100 mM stock solution of isopropyl B-D thiogalactopyranoside was added to each of the 
conical flasks which induced protein expression. The flasks were then left to be shaken at the same 
speed but with a temperature of 16oC overnight. The cultures were then collected and centrifuged for 
10 minutes at 1400 rpm. 
Cell Harvesting and Lysis 
The suspended cell pellet was then thawed and centrifuged for 15 minutes at 8000 rpm and the pellet 
was collected and suspended in lysis buffer (20 mM MES, 50 mM NaCl, 20 glycerol, pH 6.5, 1mM 
PMSF). This was then sonicated for 20 minutes on a 5s on: 5s off cycle whilst being kept on ice, the 
lysate solution was then centrifuged for 10 minutes at 14000 rpm. The supernatant was then collected 
for purification 
Protein Purification  
1L each of a wash buffer (20 mM MES, 50 mM NaCl, pH 7.5, 5% glycerol, 5 mM imidazole) and an 
elution buffer (20 mM MES, 50 mM NaCl, pH 7.5, 5% glycerol, 1 M imidazole) were made, filtered and 
degassed. The collected supernatant was then applied to a 1mL Ni2+ Sepharose (HisTrap excel) column 
attached to an AKTA FPLC. The fractions with the desired protein were collected and then mixed with 
some storage buffer (50 mM Tris- HCl, pH 7.5, 150 mM NaCl, 0.25 mM Dithiothreitol (DTT), 0.25 mM 
Ethylenediaminetetraacetic acid (EDTA), 0.1 mM Phenylmethylsulfonyl fluoride (PMSF), 25% glycerol). 
SDS PAGE- Identification 
20 µL of the collected protein fraction and 20 µL of loading buffer were mixed in 0.5 mL Eppendorf 
tubes. The mixture was then boiled at 90oC for ten minutes. This was then loaded onto a 
polyacrylamide gel which was run at 120V and 400 mA for around 100 minutes in an anode and 
cathode buffer. 
The gel was then stained with Coomassie blue staining solution for 30 minutes and then destained by 
heating it in water in a microwave until most of the dye was removed. 
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All buffers and solutions required for the SDS Page are as follows: 
- Loading buffer: 100 mL (9.46 g trizma base, 1 mL mercaptoethanol, 1 g SDS, 10 mL glycerol, 
0.01 g bromophenol blue, pH 6.8) 
- Anode buffer: 500 mL (12.11 g trizma base, pH 8.9) 
- Cathode buffer: 500 mL (6.055 g trizma base, 6.96 g tricine, 0.5 g SDS, pH 8.25) 
- Staining solution: 500 mL (1.25 g Coomassie blue, 225 mL ethanol, 50 mL glacial acetic acid)  
- Gel buffer: 500 mL (181.7 g trizma base, 1.5 g SDS, pH 8.45) 
- Gel page made with:    
 
Table 1: Table showing components for SDS page gels 
Component Stacking gel (4%) Separating gel (10%) 
Gel Buffer (mL) 2.5  3.33 
40% acrylamide (mL) 1 2.5 
Distilled water (mL) 3.25 2.8 
Glycerol (mL) - 1.3 
TEMED (µL) 25 25 
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4.2 SRPIN340 Toxicity Testing – Breast Cancer 
4.2.1 Initial Cell Culturing 
MC47 and MDA breast cancer strains donated by breast cancer patients were collected and washed 
with phosphate-buffered saline (PBS), pH 7.4 in a cell culture flask. The cells were then washed with 
trypsin and left in a CO2 incubator for about 5 minutes to detach the cells from the flask walls. A 
microscope was used to confirm cell detachment. The cells were washed again with PBS to inhibit 
the function of the trypsin. The cells were then removed from the flasks and centrifuged at 200 x g 
for five minutes. The supernatant was discarded, and the cells were kept. 10 µL of each strain was 
extracted and stained with 10µL trypan blue cell stain and then counted in an automated cell 
counter. To get more accurate results, the cell suspension was diluted so an estimated 5000 cells 
were present in each well as shown in Table 2. 
 
Table 2: Live cell counts, and calculations used for the determination of cell concentration 
Cell 
Strain 
Number of live 
cells (106/ mL) 
Concentration 
required (104/ mL) 





MCF7 5.4 5 140  14.86  
MDA 1.7 5 440  14.56  
 
The MDA strain was mixed with Dulbecco’s modified Eagle medium (DMEM) whilst the MC47 strain 
was mixed with minimal essential medium (MEM). A 12x8 well plate was chosen for each strain and 
each well was filled with 100 µL of cells. These well plates were then left in a CO2 incubator 
overnight. 
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Both cell strain media were discarded and substituted with a 100 µL of 5% foetal bovine solution 
(FBS) and then both strains were incubated in CO2. Eleven solutions of differing SRPIN340 
concentrations were prepared through serial dilutions with the starting amount being 50 µM of 
SRPIN340 dissolved in 0.1% dimethyl sulfoxide (DMSO) in water. The published IC50 value of 
SRPIN340 is 0.96 µM, therefore, all concentrations needed to be higher.62 The solutions were then 
added to the wells are illustrated in Figure 12. The plates were left to incubate for three days. After 
the incubation, half of the wells were stained with calcein acetoxymethyl (calcein-AM) and the other 
half with Alamar Blue. These dyes were chosen as they fluoresce when they come into contact with 
live cells.  A microplate reader (CLARIOstar) was used to measure the fluorescence to come with 


















Figure 12: Illustration of cell wells, cell concentrations and cell stains 
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4.3 Synthesis 
4.3.1 General Reaction Mechanism 
 
 
Figure 13: Reaction mechanism for the synthesis of SRPIN340 
 
 
Figure 13 outlines the reaction mechanism of the synthesis of SRPK1 and the consequent synthesis 
of the chosen novel compounds. Stage one consists of the nucleophilic substitution of the fluoride 
ion in the 1- fluoro-2-nitro-4-(trifluoromethyl)benzene molecule with either piperidine or the other 
nucleophiles needed for the synthesis of the selected compounds. Stage 2 is the reduction of the 
nitro group to an amine group which is necessary for stage 3. The final stage will be the nucleophilic 
attack of the acyl chloride by the amine with triethylamine being present to mop up and residual 
protons. Since all the reactants for each synthesis fall in the same molecular groups, the mechanisms 
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4.3.2 Synthesis of SRPIN340: 
The reaction protocol used was copied from the procedure stated by Fukuhara et al. in the 







































Figure 14: Reaction scheme for the synthesis of SRPIN340 
• 8-10: 9 (440 µL, 4.4 mmol) and 8 (570 µL, 2.6 mmol) were combined and dissolved in DMF (2 
mL) at room temperature and stirred for an hour. Water was added to the mixture. The 
solution then underwent extraction with diethyl ether with the combined organic layers 
being washed with brine, dried with magnesium sulphate then being filtered and dried in 
vacuo. Compound 10 (1-[2-nitro-4- trifluoromethyl)phenyl] piperidine) is an orange solid ( 1 
g, 3.64 mmol, 90% yield). 1H NMR (400 MHz, Chloroform-d) δ 8.03 (dd, J = 2.3, 0.9 Hz, 1H), 
7.65 – 7.56 (m, 1H), 7.13 (d, J = 8.8 Hz, 1H), 3.12 (dd, J = 6.4, 4.2 Hz, 5H), 1.77 – 1.59 (m, 5H). 
 
• 10-11: Anhydrous tin dichloride (3.5 g, 9.3 mmol), 10 (680 mg, 2.4 mmol), concentrated HCl 
(2.8 mL, 17 mmol) and methanol (20 mL) at 0 oC were mixed in a round bottom flask. The 
mixture was allowed to reach room temperature and was stirred overnight. The acid was 
quenched with saturated sodium bicarbonate solution and the product was extracted with 
ethyl acetate. The combined collected organic layers were washed with brine and dried with 
magnesium sulphate, filtered and dried in vacuo.  
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Compound 11 {1-[2-amino-4-(trifluoromethyl) phenyl] piperidine} is a cream coloured solid 
(0.5 g, 2.04 mmol, 77% yield). 1H NMR (CDCl3, 400 MHz) δ 1H NMR (400 MHz, Chloroform-d) δ 
7.04 – 6.90 (m, 4H), 4.06 (s, 2H), 2.85 (d, J = 6.1 Hz, 4H), 1.71 (q, J = 5.6 Hz, 4H), 1.26 (s, 1H). 
• 11-1:  Triethylamine (0.6 mL, 3 mmol), 12 (1.8 g, 2.04 mmol) and 11 (500 mg, 1 mmol) were 
dissolved in methanol (5 mL) at 0oC and left to stir for 2 hours. Water was added, and the 
product was extracted thrice with ethyl acetate. The combined organic layers were washed 
with brine, dried with magnesium sulphate, filtered then dried in vacuo. The product was 
then purified using a silica coloumn. Compound 11: N-[2-(1-piperidinyl)-5-
(trifluoromethyl)phenyl] isonicotinamide  (SRPIN340) is a white solid (0.62 g,  1.78 mmol, 
87.32% yield) ). 1H NMR (400 MHz, Chloroform-d) δ 9.53 (s, 1H), 8.90 – 8.83 (m, 3H), 7.80 – 7.73 (m, 
2H), 7.39 (dd, J = 8.3, 2.0 Hz, 1H), 7.28 (d, J = 16.8 Hz, 2H), 1.78 (p, J = 5.5 Hz, 5H), 1.71 – 1.64 (m, 3H). 
 
 






















































Figure 15: Reaction scheme of the Synthesis of 4-fluoro-3-methyl-N-(2-(2-methyl-3-oxopiperazin-1-yl)-5-
(trifluoromethyl)phenyl) benzamide 
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• 8-14:  13 (0.2 g, 1.8 mmol) and 8 (0.19 g, 0.9 mmol) were dissolved in DMF (2 mL) at room 
temperature and stirred for an hour. Water was added to the solution and the product was 
extracted with diethyl ether with the combined organic layers being washed with brine, 
dried with magnesium sulphate then being filtered and dried in vacuo. Compound 14 [3-
methyl-4-(2-nitro-4-(trifluoromethyl) phenyl) piperazin-2-one] is a yellow solid (0.14 g, 0.461 
mmol, 51.8% yield) 1H NMR (400 MHz, Chloroform-d) δ 8.31 (s, 1H), 8.02 – 7.79 (m, 3H), 
7.28 (d, J = 18.6 Hz, 3H), 6.40 (s, 1H), 4.15 (q, J = 7.2, 6.3 Hz, 2H), 3.56 – 3.32 (m, 3H), 3.16 – 
2.96 (m, 2H), 1.46 – 1.26 (m, 5H). 
• 14-15: Compound 14 (0.14 g, 0.5 mmol) anhydrous tin dichloride (2.3 g, 12.16 mmol) 
concentrated HCl (2 mL) and methanol (10 mL) at 0oC were mixed in a round bottom flask. 
The mixture was allowed to reach room temperature and heated at reflux for 30 minutes. 
The acid was quenched with saturated sodium bicarbonate solution and the product was 
extracted with ethyl acetate. The combined collected organic layers were washed with brine 
and dried with magnesium sulphate, filtered and dried in vacuo. Compound 15 [4-(2-amino-
4-(trifluoromethyl) phenyl)-3-methylpiperazin-2-one] is a cream coloured solid (0.14g, 0.29 
mmol, 57.14%) 1H NMR (400 MHz, Chloroform-d) δ 7.26 (s, 1H), 7.04 (s, 0H), 6.97 (s, 1H), 
4.11 (q, J = 7.2 Hz, 1H), 3.65 (s, 0H), 3.47 (q, J = 7.0 Hz, 34H), 1.42 (s, 10H). 
15-17:  Triethylamine (0.6 mL, 3 mmol) 15 (0.06g, 0.22 mmol) and 16 (0.06 g, 0.4 mmol) 
were dissolved in methanol (5 mL) at 0oC and left to stir for 2 hours. Water was added, and 
the product was extracted thrice with ethyl acetate. The combined organic layers were 
washed with brine, dried with magnesium sulphate, filtered then dried in vacuo. The product 
was then purified using a silica gel chromatography (1:1 ethyl acetate: hexane). Compound 
17: 4-fluoro-3-methyl-N-(2-(2-methyl-3-oxopiperazin-1-yl)-5-(trifluoromethyl)phenyl) 
benzamide appeared to be a white solid but NMR and Mass spectra indicated this was not 
made. 
35 | P a g e  
 
 























































• 15-19: Half of the amount of 15 created in the synthesis of 17 was used in this process. 
Triethylamine (0.6 mL, 3 mmol), 18 (0.07g, 0.4 mmol) and 15 (0.06g, 0.22 mmol) were 
dissolved in methanol (5 mL) at 0oC and left to stir for 2 hours. Water was added, and the 
product was extracted thrice with ethyl acetate. The combined organic layers were washed 
with brine, dried with magnesium sulphate, filtered then dried in vacuo. The product was 
then purified using a silica gel chromatography (1:1 ethyl acetate: hexane). Compound 19: 
2,3-difluoro-4-methyl-N-(2-(2-methyl-3-oxopiperazin-1-yl)-5-(trifluoromethyl)phenyl) 
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Figure 17: Reaction scheme of the synthesis Synthesis of 2,3-difluoro-N-(2-(hexahydropyrrolo[1,2-a] pyrazin-2(1H)-yl)-5-
(trifluoromethyl) phenyl)-4-methylbenzamide 
 
• 8-21:  20 (0.15 g, 1.18 mmol) and 8 (0.12g, 0.57 mmol) were dissolved in DMF (2 mL) at room 
temperature and stirred for an hour. Water was added to the solution and the product was 
extracted with diethyl ether with the combineCF3d organic layers being washed with brine, 
dried with magnesium sulphate then being filtered and dried in vacuo. 21: 2-(2-nitro-4-
(trifluoromethyl) phenyl) octahydropyrrolo [1,2-a] pyrazine is a dark orange solid (0.13 g, 
0.41 mmol, 35% yield) 1H NMR (400 MHz, Chloroform-d) δ 7.99 (s, 1H), 7.63 (dd, J = 8.8, 2.2 
Hz, 1H), 7.17 (d, J = 8.8 Hz, 1H), 3.95 (s, 0H), 3.41 – 3.04 (m, 4H), 2.89 (d, J = 30.7 Hz, 4H), 
2.48 (td, J = 11.0, 3.3 Hz, 1H), 2.29 (q, J = 8.8 Hz, 1H), 2.14 (d, J = 0.8 Hz, 1H), 1.96 – 1.69 (m, 
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• 21-22: 21 (0.13 g, 0.41 mmol, anhydrous tin dichloride (2.3g, 12.16 mmol), concentrated HCl 
(2 mL) and methanol (10 mL) at 0oC were mixed in a round bottom flask. The mixture was 
allowed to reach room temperature and heated at reflux for 30 minutes. The acid was 
quenched with saturated sodium bicarbonate solution and the product was extracted with 
ethyl acetate. The combined collected organic layers were washed with brine and dried with 
magnesium sulphate, filtered and dried in vacuo.  
Compound 22: 2-(hexahydropyrrolo[1,2-a] pyrazin-2(1H)-yl)-5-(trifluoromethyl)aniline is a 
light yellow coloured solid (0.08, 0.28 mmol, 72% yield) 1H NMR (400 MHz, Chloroform-d) δ 
7.16 – 6.85 (m, 1H), 4.23 – 3.91 (m, 1H), 3.46 (q, J = 7.0 Hz, 0H), 3.23 (dt, J = 10.9, 2.2 Hz, 0H), 
3.16 – 3.05 (m, 1H), 2.85 (td, J = 11.5, 11.0, 3.0 Hz, 0H), 2.54 (dd, J = 10.9, 9.8 Hz, 0H), 2.40 
(td, J = 11.7, 11.1, 3.1 Hz, 0H), 2.31 – 2.12 (m, 1H), 2.02 (s, 0H), 1.93 – 1.68 (m, 1H), 1.59 – 
1.35 (m, 0H), 1.21 (dt, J = 19.7, 7.1 Hz, 1H). 
• 22-23:  Triethylamine (0.6 mL, 3 mmol), 18 (0.05 g, 0.3 mmol) and 22 (0.04, 0.14 mmol) were 
dissolved in DCM (5 mL) at 0oC and left to stir for 2 hours. Water was added, and the product 
was extracted thrice with ethyl acetate. The combined organic layers were washed with 
brine, dried with magnesium sulphate, filtered then dried in vacuo. The product was then 
purified using a silica gel chromatography (1:1 ethyl acetate:hexane). Compound 23: 2,3-
difluoro-N-(2-(hexahydropyrrolo[1,2-a] pyrazin-2(1H)-yl)-5-(trifluoromethyl) phenyl)-4-
methylbenzamide is a brown/ orange solid (0.04 g, 0.09 mmol, 66.66% yield). 1H NMR (400 
MHz, Chloroform-d) δ 7.56 (ddd, J = 8.4, 6.5, 1.9 Hz, 2H), 7.01 – 6.85 (m, 2H), 4.37 (q, J = 7.1 
Hz, 3H), 3.43 (d, J = 13.8 Hz, 0H), 3.30 – 3.15 (m, 0H), 3.10 (q, J = 7.3 Hz, 2H), 2.41 – 2.22 (m, 
5H), 1.38 (td, J = 7.2, 3.6 Hz, 7H), 1.30 – 1.17 (m, 1H). 
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yl)-5-(trifluoromethyl)phenyl)-3-methylbenzamide (24)  
Figure 18: Reaction scheme of the synthesis of 4-fluoro-N-(2-(hexahydropyrrolo[1,2-a] pyrazin-2(1H)-yl)-5-
(trifluoromethyl) phenyl)-3-methylbenzamide 
 
• 22-24: Taking half of the amount of 22 created in the synthesis of 23 was used in this 
process. Triethylamine (0.6 mL, 3 mmol), 16 (0.05 g,0.3 mmol) and 22 (0.04 g, 0.14 mmol) 
were dissolved in methanol (5 mL) at 0oC and left to stir for 2 hours. Water was added and 
the product was extracted thrice with ethyl acetate. The combined organic layers were 
washed with brine, dried with magnesium sulphate, filtered then dried in vacuo. The 
product was then purified using a silica gel chromatography (1:1 ethyl acetate: hexane). 
Compound 24: 4-fluoro-N-(2-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)-5-
(trifluoromethyl)phenyl)-3-methylbenzamide is a brown solid (0.021, 0.05 mmol, 42% yield) 
1H NMR (400 MHz, Chloroform-d) δ 10.31 (s, 1H, NH), 7.95 – 7.83 (m, 2H, 2CH), 7.33 (d, J = 
1.4 Hz, 1H, CH), 7.13 (q, J = 8.7, 7.1 Hz, 1H, CH), 7.07 – 6.90 (m, 2H, 2CH), 3.52 – 3.20 (m, 6H, 
3CH2), 3.16 (qd, J = 7.3, 1.2 Hz, 2H, CH2), 2.34 (s, 2H, CH2), 2.27 (d, J = 1.8 Hz, 2H, CH3, CH), 
2.13 – 1.91 (m, 4H, 2CH2), 1.23 (td, J = 7.1, 1.1 Hz, 2H, CH2). 
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5. Results and Discussion 
 
5.1 Protein Harvesting and Characterisation 
 
For this research, the SRPK1 protein needed to be harvested. This was to test experimentally how 
well the novel compounds bound to the protein.  The procedure for how the harvesting was 
achieved is outlined in the previous chapter. After the SRPK1 protein was harvested from the E. coli, 
it was run through an SDS page and also through an LC/MS to characterise the protein. The protein 
from the plasmid used was only a partial version of the original protein. The plasmid that was 
donated from the Adams group was a truncated version. In the full-length SRPK1 protein, there is 
the generic kinase core as well as a long spacer region found between the two lobes of the core. It 
was found by Ngo et al.  that the purification of the full-length protein caused its degradation as 
there was a cleave that occurred in the spacer region.63 When this space region was removed, Ngo 
et al. found that purification was then possible without compromising its kinase activity. It was the 
newly truncated version (SRPK1ΔNS3) that was donated in the plasmid. The comparison between 
the full length and the truncated is illustrated in figure 19. 
 
Figure 19: Illustrated comparison of the full length and truncated SRPK1 protein 
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Unfortunately, the papers by the Adams group featuring this truncated protein did not mention its 
weight. The work by Ngo came with a different weight usually around the 40 kDa weight. This was 
particularly interesting because when the SDS page and mass spectrometry was conducted, a 
protein weight of 35 kDa was deduced. The SDS page can be seen in figure 20 and the mass 
spectrum data in figure 21. 
 
















Figure 21: Mass spectra following protein purification. As seen in the top, seems to be clear peak showing mass of 35418 Da. This 
could ASF2 
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Further reading and analyses show that the protein being expressed with the weight of 35 kDa might 
be Alternative Splicing Factor 2 (ASF2). It has been confirmed to have a weight of around 33 kDa.64 It 
is a protein necessary in most alternative splicing and acts in mRNA translation and nuclear export 
post-slicing.65 The expression of this protein is not a bad result. Though the preferred protein would 
have been SRPK1, work that was planned would have tested the practical interactions between the 
synthesised molecules and both SRPK1 and ASF2 since both proteins often work in tandem.  
As to why little to no levels of SRPK1 was produced, this could be perhaps be explained in the FPLC 
purification step. Since ASF2 is the smaller protein, it is more like to elute at a faster time compared 
to SRPK1 if assuming both proteins have similar polarities. If this process was to be repeated, a 
longer run time to look for a second peak which might indicate the presence of a second protein. A 
second run would have to be done perhaps using size exclusion chromatography since the weight is 
known. Also, as seen in the SDS page, the collected protein was not pure. This could have been due 
to there being other histidine-tagged or histidine-rich proteins from a previous use trapped in the 
column even after it had been washed. 
 
5.2 Computational Methods 
Computational methods were used to find potential new lead compounds which could be more 
potent and more effective than SRPK1. The structure of SRPIN340 was used as a scaffold and the 
molecule was split into three fragments as seen in figure 22. Different libraries were created to find 
substitutions for each fragment then these libraries were combined and put through the software 
KNIME which created a new library made from different combinations of the fragments. Outlined 
below is the process of discovery. 
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Figure 22: The different fragments of SRPIN340 used to create the libraries 
 
5.2.1 Compound Library Formation 
As mentioned before, different libraries were created from different parts of the SRPIN340 
molecule. The alternatives used to make these libraries were sourced from different places. 
Fragment one was sourced from the SwissBioisostere database and can be seen in Figure 23.66 Swiss 
Bioisostere is a database of molecular replacements. It provides information on molecular 
replacements and how they perform in biochemical assays to give an idea on what bioisosteric 
modifications can be made to a lead compound to optimise it. This software was chosen because 
suggested replacements for the fragments came from published data. Also, information on the 
biochemical assays helped give a better idea of the best replacements. 




Figure 23: Picture showing the use of SwissBioisostere 
 
The list was generated into a CSV file. The lists for substitutes for fragment two and three were 
sourced from ZINC15 which is a database of commercially available compounds.67  
 
After gaining the libraries, they were put through KNIME software in three different entry ports as 
pictured in figure 24.  Through these ports, bioisosteric transformations were made and then 
different combinations from the three lists were then made. The nodes used in the KNIME workflow 
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Figure 24: KNIME workflow used in the creation of analogues through combinations of the three libraries. 
 
The nodes in the blue rectangle pictured in figure 24 were the ports through which the libraries were 
introduced to the workflow. After all 3 nodes had the libraries uploaded to them, the structure 
sketcher in the yellow square was used to upload the molecular structure for SRPIN340. This enabled 
the workflow to have a scaffold to work with. The nodes in brown sorted out the libraries to ensure 
they were in the correct format needed to apply the transformations. The libraries already came 
with each bioisosteric replacement having a score so the filters in green took the 100 molecules with 
the highest score in each library. The nodes in black (meta nodes) were each programmed to add the 
bioisosteric changes to the scaffold through different combinations. Each library was added in 
sequenced steps and after all combinations were completed, the new library was passed through 
the nodes in red which allowed only the product made to be visible. The RDKit Descriptor node gave 
properties to the newly formed products. It gave information such as LogP and molecular weight. 
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The final list of all the combinations had around 250 thousand molecules. With such a large number 
of molecules, it was imperative to deduce which were most likely to have an inhibitory effect on the 
target protein’s binding site. To determine this, a 3D pharmacophore study was needed and the 
software Pharmit was used. An X-ray crystal structure of SRPK1 as shown in Figure 25 was found 
from the Protein Data Bank (PDB) and was derived by Morooka et al.21 The crystal structure with 
SRPIN340 bound to the receptor had the label 4WUA with the ligand 3UL and it is with this, the 
pharmacophore was built. 
 
Figure 25: X-ray structure of SRPK1 
 
The library list generated from before by KNIME was uploaded to the Pharmit software and the 
pharmacophore model searched through the generated list. The attributes that determined the 
pharmacophore’s biological activity were chose as shown in the yellow rectangle in figure 26. There 
were over 25000 hits which were ranked in order of Root Mean Squared Deviation (RMSD). RMSD is 
the variation in the position of atoms in the pharmacophore when compared to the original 
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conformation and positions of the original pharmacophore. Therefore, the smaller the RMSD, the 
higher the similarity of a molecule to the compound in structure. 
 
Figure 26: Pharmacophore modelling to score molecules in the library. Parameters set for the pharmacophore can be 
seen highlighted in the yellow rectangle. 
 
Though there was a high number of molecules, it was noticed that a lot of them were repeated just 
in slightly different conformations so, in another effort to lower the numbers, a restriction was 
placed to only consider the best conformation of each molecule. This still generated a large list. The 
list was downloaded and put through another KNIME workflow. 
The new workflow in KNIME had nodes to help filter out molecules using a set of parameters. These 
parameters were to find molecules that followed Lipinski’s rule of 568 with a few modifications, had a 
reasonable binding affinity and to ensure that synthesis was possible. The parameters in detail were 
Lipinski’s rule of five which outline certain properties most molecules need to have to be potentially 
effective as drugs.   
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Applying this to the workflow, molecular weight was one of the most important properties given. 
Lipinski’s rule mentions that potential drugs should have a molecular weight less than 500 g/mol and 
therefore all molecules with a weight of over 450 were excluded. It must be emphasised how 
important hydrophilicity is as this determines whether a drug can be easily absorbed by the 
gastrointestinal tract. One of the major problems with SRPIN340 was its inability to be easily 
dissolved in water. Using Lipinski’s rule, all molecules with a LogP of higher than 5 were excluded to 
ensure solubility was possible in water. Also, molecules with more than 5 hydrogen bond donor and 
10 hydrogen bond acceptors were also excluded. 
Outside of Lipinski’s rule, one of the other filters used included affinity scores. All molecules with a 
score higher than -11 were excluded. A lot of the molecules scored between -11 and -12. In 
comparison, SRPIN340 had a score of -9.7, therefore, a score lower than that was needed for a more 
potent inhibitor. Another filter used focused on the fragments themselves. It was noticed when 
going through the list that some of the fragments repeated themselves as expected but a lot of them 
were not necessarily easy to synthesise. Some were searched for in databases including Sigma 
Aldrich, Molbase, Reaxys and Scifinder. These fragments were either not easy to make and required 
unavailable environments or they were simply not available in the catalogues for purchase. It was 
therefore not reasonable to choose the molecules that had these fragments and so such molecules 
were filtered out. 
After all the filtering was done, lead compounds could not be chosen simply on their affinity scores 
or a single factor, therefore, the Pareto Principle was used. The Pareto principle states that most 
things are not distributed evenly. This means some things contribute more to the whole than others. 
An example would be in a work situation where 20% of the workers do the vast majority results 
whilst the remaining 80% do not contribute as much. It helps in decision making especially when 
figuring out where to place the highest priority instead of casting a wide net. Here, it was 
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determined that some properties contribute more to the molecules biological activity in comparison 
to others. The two most important factors chosen were affinity scores and LogP.  
With this, a scatter plot was created. Due to the importance of both factors, a compromise had to be 
made and it meant not choosing a molecule with a low hydrophobicity whilst sacrificing binding 
affinity and vice versa. When this reasoning was used, molecules that fell near the curve as shown in 
figure 27 suited both factors. From this, 4 molecules were chosen, and the needed fragments were 
bought and synthesised as described in the synthesis.  
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5.3 Novel Compound Selection 
 
After the computational studies as outlined in the previous chapter was completed. Four molecules 
were chosen out of the thousands created. This selection was made based on LogP, molecular 
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The particulars of each molecule can be seen below in Table 3  
 





























433.43 3.638 -11.63 1.14 
 
 
As shown, there were stronger binding affinities in all the molecules chosen compared to SRPIN340.  
All the components needed to synthesise the molecules were then ordered. Unfortunately, not all 
the fragments arrived. Only two of fragments 2 and two from fragment 3 ever arrived and they did 
not correspond with each other. It was decided that the synthesis will carry on and synthesis 
molecules with the fragments available whilst mixing and matching the fragments. In the end, 4 new 
molecules could be potentially made. These are illustrated in Figure 29. 
 
 













































































Figure 29: Illustration of the combinations of fragments 
 
 
 The synthesis of each molecule is detailed in the previous chapter including analytical data. Copies 
of analytical data can be found in the appendix. The molecules containing the 3-methylpiperazin-2-
one fragment proved difficult to synthesise in every stage of the reaction. All analytical data showed 
unexpected information and the generic reaction had to be modified many times to find the 
molecule needed. Some tweaks included using heat and increasing the amount of SnCl2 used as well 
as using more concentrated acid in the reduction step.  
After the synthesis, unfortunately, there was not enough time to test the molecules on the SRPK1 
protein to test for its activity using experimental methods. Also, in vivo testing could not be done on 
the mammalian cells.  
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5.4 In vitro toxicity testing of SRPIN340 on mammalian cells. 
 
Two cell strains from metastatic tumours found in breast cancer patients were used for the toxicity 
testing. Breast cancer cells were chosen due to studies showing that the overexpression of SRPK1 
lessens apoptosis in breast cancer cells.69 The results for the toxicity testing of SRPIN340 on the two 
breast cancer cell strains can be seen in figure 30. 
 
Figure 30: Graph showing SRPIN340 toxicity. 
For the MCF7 strain, SRPIN340 toxicity could be seen in concentrations above 25 µM in cells stained 
with Alamar blue but with the cells stained with calcein AB, toxicity could be seen in concentrations 
above 10 µM. In the MDA strain, toxicity showed in concentrations above 25 µM and it was the 
same for stains.  




The synthesis of SRPIN340 was successful and was produced with a high yield of 87.32%. But this did 
not replicate in the production of the novel compounds. Compounds 17, 19 were not made and the 
rest of the novel compounds were produced but in very low titres. The particular reason this could 
have happened is not ascertained but there are possible theories. 
Firstly, in stage 1, the nucleophiles used were piperazines are less basic than piperidine. With this 
reduced basicity, the piperazines are less nucleophilic and will be more difficult to do the substation. 
This can be seen in drops in yields. SPRIN240 had a yield of 90% in stage one compared to the rest of 
the molecules with a maximum yield of 51.8% in the first stage. In a paper by Magano et al,70 sodium 
tert-butoxide, a palladium catalyst and toluene with the entire reaction being done in reflux showed 
success so this might be an avenue to take in future.  
In stage 2, an instant colour change was visible when the reaction was started. The solution went 
from brightly coloured yellow/orange to light yellow then to clear, so a reaction was evident. Yet 
when the extraction was done, the was little to no product produced at all. In acidic conditions like 
that needed for the reduction, the piperazines can become reactive. The keto group on the 3-
methylpiperazin-2-one especially reacts in acidic conditions since it protonates it become a hydroxy 
group. This is evident in the product being made. The octahydropyrollo[1,2-α]pyrazine with fairly 
good yields of around 70% since this acid reaction did not affect it. In the future, blocking the keto 
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6. Conclusions  
  
The known kinase inhibitor SRPin340 was successfully synthesised with its presence being 
determined with NMR spectroscopy. Toxicity studies were conducted using two strains of 
mammalian breast cancer cells. The studies showed the concentrations of around 25 µM 
caused toxicity.  
 SRPK1 Protein was also successfully purified from recombinant E. coli cells. The protein was then 
purified using nickel-affinity FPLC and the presence and weight of the protein were determined 
through an SDS PAGE. The results from the page showed the protein to have a weight of around 
35 kDa. This was also confirmed by LC-MS. This weight did not match previous work using the same 
plasmid which gave a weight of 45 kDa. Even when the expression was repeated, the same 
35 kDa weight was the result. This protein purified is believed to be the ASF2 protein. 
Using SRPIN340 as a scaffold, three libraries were sourced from ZINC15 and SwissBioiostere with 
each library representing a fragment of the scaffold. These libraries were put through KNIME which 
created different combinations of the fragments to create new analogues of SRPIN340 to form a 
new library.  
A 3D pharmacophore study was conducting using SRPIN340 complexed to SRPK1. The crystal 
structure for the complex was generated by Morooka et al. and was used in the Pharmit software. 
The forces that were felt to be vital in the biological activity of the pharmacophore was highlighted 
and with the information, the software screened through the new library to find the most likely 
biologically active. It also ranked the molecules according to their affinity scores. The list was 
downloaded to create another library.  
 A new KNIME workflow was created to help filter molecules that were too heavy, too hydrophobic, 
had low affinity scored and had fragments that were not easy to purchase or synthesise. Using 
Pareto’s principle in a scatter plot, four molecules were chosen that had both low LogP values and 
high-affinity scores. The four fragments from the four molecules were then purchased for synthesis.  
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Not all the fragments arrived so with the ones available, different combinations of the fragments 
were synthesised to create new molecules. Two were very easy to synthesise but the other two did 
not create the final product intended. This was due to unpredicted interactions that certain 
functional groups had with catalysts and the reagents. Unfortunately, experimental binding studies 
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7. Further work  
  
In this section, improvements that can be made to this study will be discussed as well as what 
further work can be done.   
Firstly, as it was not known why the protein harvested from the E. coli cells was smaller than 
anticipated. To figure out why, sequencing of the plasmid can be done to find the gene sequence, so 
a more accurate weight can be deduced. PCR can also be done on the plasmid to ensure the gene is 
still in the plasmid. From this, if the problem lies with the plasmid, new plasmids can be gotten or 
made. If it lies with the technique in protein expression, the experiment can be redone after 
evaluating. Size exclusion and longer runs could be done to ensure the purification of SPRK1 in the 
future also. 
One of the biggest problems faced was the synthesis of molecules 18 and 25. There were problems 
in every stage of the reaction and some stages had to be done multiple times with different 
conditions and working in small quantities did not allow for easy product retrieval from separations. 
In the future, trying with larger amounts might help in recuperating more product. Also during 
reactions, blocking and protecting reactive functional groups from making unwanted interactions 
could increase the possibilities of the product being made. 
As mention in previous chapters, a lot of the fragments ordered did not arrive which made it difficult 
to create the molecules chosen from the computational studies. For future work, getting hold of 
those fragments and synthesising the molecules would be greatly advantageous to compare to the 
computational predictions.  
Due to time constraints, toxicity and binding studies could not be conducted on the synthesised 
molecules. With SRPIN340 as a control, comparisons of potency and binding strength between the 
molecules and SRPIN340 can be made. This is essential to argue that the new molecules would be 
better.  
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